These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3531951)

  • 21. Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer.
    Martoni A; Pacciarini MA; Pannuti F
    Eur J Cancer Clin Oncol; 1985 Jul; 21(7):803-6. PubMed ID: 3862582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary observations on intravenous idarubicin (4-demethoxydaunorubicin) in the chronic and accelerated phase of chronic myelogenous leukemia.
    Battista R; D'Emilio A; Vespignani M; Pacciarini MA; Dini E
    Tumori; 1986 Aug; 72(4):389-93. PubMed ID: 3464125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
    Ganzina F; Pacciarini MA; Di Pietro N
    Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma.
    Hakes TB; Daghestani AN; Dougherty JB; Weiselberg L; Raymond V
    Cancer Treat Rep; 1985 May; 69(5):559-60. PubMed ID: 3859369
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer.
    Casper ES; Raymond V; Hakes TB; Currie VE; Kaufman RJ
    Cancer Treat Rep; 1987 Dec; 71(12):1289-90. PubMed ID: 3480045
    [No Abstract]   [Full Text] [Related]  

  • 26. [Evaluation of 4-demethoxydaunorubicin toxicity (IMI 30). Preliminary data].
    Nobile MT; Pronzato P; Campora E; Ardizzoni A; Grimaldi A; Lionetto R; Repetto L; Rosso R
    G Ital Chemioter; 1985; 32(1):29-30. PubMed ID: 3913619
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia.
    Hayat M; Hurteloup P; Parmentier C; Carde P; Pico JO; Schlumberger M; Chahine G; Kamioner D
    Invest New Drugs; 1984; 2(4):375-9. PubMed ID: 6595242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4-Demethoxydaunorubicin administered orally in advanced breast cancer. A phase II study.
    De Lena M; Brandi M; Bozzi D; Calabrese P; Romito S
    Tumori; 1988 Feb; 74(1):65-70. PubMed ID: 3162625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma.
    Scher HI; Yagoda A; Ahmed T; Budman D; Sordillo P; Watson RC
    Cancer Chemother Pharmacol; 1985; 14(1):79-80. PubMed ID: 3855289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
    Kris MG; Gralla RJ; Kelsen DP; Casper ES; Burke MT; Fiore JJ; Cibas IR; Heelan RT
    Am J Clin Oncol; 1985 Oct; 8(5):377-9. PubMed ID: 3864366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of a polychemotherapeutic regimen including Idarubicin (4-demethoxydaunorubicin) in relapsed acute lymphocytic leukemia.
    Mandelli F; Testi AM; Aloe Spiriti MA; Giona F; Meloni G; Moleti ML; Amadori S; Pacciarini MA
    Haematologica; 1986; 71(1):34-8. PubMed ID: 3084353
    [No Abstract]   [Full Text] [Related]  

  • 32. New anthracycline analogs in advanced breast cancer.
    Bonfante V; Ferrari L; Brambilla C; Rossi A; Villani F; Crippa F; Valagussa P; Bonadonna G
    Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1379-85. PubMed ID: 3470179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma.
    Coonley CJ; Warrell RP; Straus DJ; Young CW
    Cancer Treat Rep; 1983 Oct; 67(10):949-50. PubMed ID: 6578873
    [No Abstract]   [Full Text] [Related]  

  • 34. Phase II study of 4-demethoxydaunorubicin in patients with adenocarcinoma of the upper gastrointestinal tract.
    Einzig A; Kelsen D; Cheng E; Sordillo P; Raymond V; Magill G
    Cancer Treat Rep; 1984 Nov; 68(11):1415-6. PubMed ID: 6594197
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase II study of oral 4-demethoxydaunorubicin in previously treated (except anthracyclines) metastatic breast cancer patients.
    Kolarić K; Mechl Z; Potrebica V; Sopkova B
    Oncology; 1987; 44(2):82-6. PubMed ID: 3472133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of 4-demethoxydaunorubicin in advanced colorectal carcinoma.
    Harper HD; Kemeny NE; Ahmed T; Cheng E; Arena F; Sordillo P; Faye L
    Cancer Treat Rep; 1984 Apr; 68(4):689-90. PubMed ID: 6585273
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical study of detorubicin. EORTC Clinical Screening Group.
    Recent Results Cancer Res; 1980; 74():184-91. PubMed ID: 7444139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New anthracyclines in the treatment of solid tumors in the advanced stage].
    Pannuti F; Martoni A; Lelli G; Camaggi CM; Strocchi E; Fruet F
    G Ital Chemioter; 1985; 32(1):49-56. PubMed ID: 3868636
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase II evaluation of piperazinedione in metastatic breast carcinoma.
    Palmer RL; Samal BA; Vaughn CB; Tranum BL
    Cancer Treat Rep; 1977 Dec; 61(9):1711-2. PubMed ID: 340035
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin.
    Kavanagh JJ; Yeung KY; Savaraj N; Krakoff IH
    Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1187-9. PubMed ID: 3865774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.